/CLYM
CLYM Stock - Climb Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$4.28-2.28%
$0.10 (-2.28%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+157.0%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLYM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.24 – $4.32
TARGET (TP)$11.00
STOP LOSS$3.94
RISK/REWARD1:19.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.05
52W High$4.82
52W Low$1.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-82,020,000 | $-40,275,000 | $-45,135,000 | $-35,672,000 | $-20,925,000 |
| Net Income | $-73,897,000 | $-35,119,000 | $-45,244,000 | $-47,480,000 | $-20,668,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.53 | $-1.30 | $-1.72 | $-4.24 | $-1.97 |
Company Overview
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 110.3% Upside
Now
$7
Low
$9
Average
$10
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 16th 2025 | William Blair | Initiation | Outperform | - |
| October 13th 2025 | H.C. Wainwright | Initiation | Buy | $9 |
| August 15th 2025 | Robert W. Baird | Initiation | Outperform | $9 |
| June 6th 2025 | Oppenheimer | Initiation | Outperform | $10 |
| May 22nd 2025 | BTIG Research | Initiation | Buy | $7 |
| December 2nd 2024 | Leerink Partners | Initiation | Outperform | $10 |
Earnings History & Surprises
CLYMBeat Rate
30%
Last 10 quarters
Avg Surprise
-35.1%
EPS vs Estimate
Beats / Misses
3/7
Last 12 quarters
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q4 23
-2.5%
$-0.13vs$-0.13
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
+13.3%
$-0.13vs$-0.15
Q2 25
-106.7%
$-0.31vs$-0.15
Q3 25
+31.6%
$-0.13vs$-0.19
Q4 25
-18.8%
$-0.19vs$-0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.16 | $-0.19 | -18.8% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.19 | $-0.13 | +31.6% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.15 | $-0.31 | -106.7% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | — | $-0.13 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-1.81 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.06 | — | — |
Q4 2023 | Dec 31, 2023 | $-0.13 | $-0.13 | -2.5% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.14 | $-0.15 | -4.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.16 | $-0.19 | -21.5% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.25 | $-0.84 | -236.0% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-0.38 | $-0.29 | +22.5% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | — | $-0.37 | — | — |
Q2 2022 | Jun 30, 2022 | $-0.43 | $-0.56 | -28.3% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | — | $-0.50 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.40 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.62 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.37 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-1.60 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $11
📈 PositiveBenzinga•Dec 18, 2025, 12:00 PM
Climb Bio Q3 EPS $(0.19) Misses $(0.14) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 12:28 PM
Climb Bio To Showcase Preclinical And Long-Term Data For Novel Antibody Therapies At 2025 ASN Kidney Week
📈 PositiveBenzinga•Oct 17, 2025, 11:05 AM
William Blair Initiates Coverage On Climb Bio with Outperform Rating
📈 PositiveBenzinga•Oct 16, 2025, 11:02 AM
BTIG Reiterates Buy on Climb Bio, Maintains $8 Price Target
📈 PositiveBenzinga•Oct 16, 2025, 10:30 AM
HC Wainwright & Co. Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $9
📈 PositiveBenzinga•Oct 13, 2025, 11:21 AM
Climb Bio Appoints Susan Altschuller As CFO
➖ NeutralBenzinga•Oct 1, 2025, 11:05 AM
BTIG Maintains Buy on Climb Bio, Raises Price Target to $8
📈 PositiveBenzinga•Sep 30, 2025, 11:26 AM
Climb Bio Reports Results From NHP Study Comparing CLYM116 To Sibeprenlimab; New Preclinical Data Show Deeper IgA Reduction And Longer Half-Life Compared To First-Gen Anti-APRIL Monoclonal Antibody
📈 PositiveBenzinga•Sep 29, 2025, 11:03 AM
BTIG Reiterates Buy on Climb Bio, Maintains $7 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 02:29 PM
Frequently Asked Questions about CLYM
What is CLYM's current stock price?
Climb Bio, Inc. (CLYM) is currently trading at $4.28 per share. The stock has moved -2.28% today.
What is the analyst price target for CLYM?
The average analyst price target for CLYM is $11.00, based on 1 analyst.
What sector is Climb Bio, Inc. in?
Climb Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CLYM's market cap?
Climb Bio, Inc. has a market capitalization of $0.29 billion, making it a small-cap company.
Does CLYM pay dividends?
No, Climb Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
ACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ANIX
Anixa Biosciences, Inc.
$3.30
Mkt Cap: $0.1B
ENTX
Entera Bio Ltd.
$1.77
Mkt Cap: $0.1B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
TTRX
Turn Therapeutics Inc.
$3.00
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to CLYM for comparison